ARS Pharmaceuticals (SPRY) Operating Income: 2022-2025
Historic Operating Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$53.2 million.
- ARS Pharmaceuticals' Operating Income fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of -$3.1 million for FY2024, which is 95.43% up from last year.
- According to the latest figures from Q3 2025, ARS Pharmaceuticals' Operating Income is -$53.2 million, which was down 11.72% from -$47.6 million recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Operating Income registered a high of $47.2 million during Q4 2024, and its lowest value of -$53.2 million during Q3 2025.
- Over the past 3 years, ARS Pharmaceuticals' median Operating Income value was -$18.7 million (recorded in 2023), while the average stood at -$19.0 million.
- Per our database at Business Quant, ARS Pharmaceuticals' Operating Income tumbled by 224.76% in 2023 and then skyrocketed by 561.54% in 2024.
- Quarterly analysis of 4 years shows ARS Pharmaceuticals' Operating Income stood at -$15.4 million in 2022, then spiked by 33.78% to -$10.2 million in 2023, then spiked by 561.54% to $47.2 million in 2024, then crashed by 144.58% to -$53.2 million in 2025.
- Its Operating Income stands at -$53.2 million for Q3 2025, versus -$47.6 million for Q2 2025 and -$37.2 million for Q1 2025.